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Nephrotic Syndrome: Is HIV Associated 
Nephropathy on Your Differential? 
Jad Al Danaf, MD, Jeffrey Marbach, MD, Sharon Li, MS4, Emily Stewart, MD
CaSE dESCrIPTIon
A 30-year old African American female with no significant 
past medical history initially presented to our emergency 
department with three days of sore throat, dysphagia, 
fever, fatigue, nausea and vomiting. She denied ear pain, 
rhinorrhea, shortness of breath or any sick contacts. Her 
social history was negative for tobacco, alcohol and illicit 
drug use. She works as a security officer, lives with her 
family and is sexually active only with her husband. On 
initial examination she was febrile to 101.9° F, with a heart 
rate of 100 beats per minute, blood pressure of 143/99 
mmHg, respiratory rate of 18 breaths per minute and an 
oxygen saturation of 99% on room air. Her only pertinent 
physical examination findings were a mildly erythematous 
oropharynx without exudates, mildly swollen uvula and 
right tonsil, bilateral tender swollen sub-mandibular 
lymph nodes and reduced breath sounds on auscultation 
of the right lower lung base.She was routinely tested for 
HIV, ruled out for group A strep, and discharged home 
with the diagnosis of viral pharyngitis on supportive care. 
Following the identification of a presumptive positive 
rapid HIV screening test with evidence of HIV-1 p24 
antigen and a reactive HIV-1 antibody on the multispot 
HIV 1 / 2 antibody test she was called to return to the ED 
for counseling regarding a positive HIV test. She reported 
continuation of her prior symptoms with worsening 
dysphagia, as well as new complaints of bilateral lower 
extremity edema to the knees. Initial laboratory testing 
revealed an elevated serum creatinine (Cr) of 2.2mg/dL 
(0.7-1.3 mg/dL) up from <1.0mg/dL one-year prior, with 
an estimated Creatinine clearance (CrCl) of 43.4 ml/min 
using the modified Cockcroft-Gault equation. She was 
admitted for further workup. A trial of IV fluid hydration 
overnight worsened her symptoms and additional labs 
demonstrated hypoalbuminemia, 4+ proteinuria with 
1+ blood, and a urine protein/creatinine ratio of 17mg/
mg (<0.2 mg/mg), consistent with nephrotic syndrome. 
Her CD4 count was 115 cells/mm3 (500-1500 cells/
mm3) with an HIV viral load of 117,148 copies/ml. 
Based off negative labs for syphilis, hepatitis panel, ANA, 
complement C3/C4, and diabetes, findings were felt to 
be consistent with HIV Associated Nephropathy (HIVAN). 
The patient underwent renal biopsy to confirm the diagnosis 
and was started on abacavir, darunavir, dolutegravir, 
lamivudine and ritonavir. Pathology results were consistent 
with HIVAN with tubulointerstitial nephritis and collapsing 
glomerulonephropathy and electron microscopy 
showed diffuse epithelial cell injury with effacement of 
foot processes and segmental collapse of glomerular 
capillary loops. Her serum Cr peaked at 2.78 on day 7 of 
her admission. Her serum Cr and urea-nitrogen steadily 
improved after just one week of HAART therapy leading 
to a 42% reduction in serum Cr (Figure 1). Additionally, 
due to her un-resolving dysphagia the patient underwent 
esophagogastroduodenoscopy, which was unremarkable. 
However, she subsequently had esophageal manometry, 
which was consistent with diffuse esophageal spasm for 
which she was started on diltiazem.
dISCuSSIon
HIV-associated nephropathy (HIVAN) is an aggressive form 
of collapsing focal segmental glomerulosclerosis and 
tubulointerstitial lesions that is observed predominantly 
in African Americans. The first descriptions of this 
disease manifestation were among African-American 
and Haitian immigrants with advanced HIV illness, which 
serve to highlight the racial disparity and genetic suscep-
tibility to HIVAN.1 The era of highly active antiretroviral 
therapy (HAART) has reduced the incidence of HIVAN; 
however, HIVAN remains the 3rd leading cause of end 
stage renal disease (ESRD) among blacks between the 
ages of 20-64 years old, with an estimated 90% of 
patients with ESRD attributed to HIVAN being of African-
American descent.2 Although incompletely understood 
it has been postulated that the pathogenesis of HIVAN 
involves several factors, including direct HIV infection of 
glomerular and tubular epithelial cells and upregulation 
of host cellular pathways involved in apoptosis and 
cell cycle arrest.3-5 As previously mentioned, current 
therapy involves initiation of HAART, along with renal 
replacement therapy and renin-angiotensin system 
inhibitors as warranted. 
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Ultimately, HIV prevention remains the best approach to 
impact the epidemiology of HIVAN. In this case report, it 
was not clear for exactly how long the patient had HIV, 
however if it was a recent transmission it would have 
been a rare case of HIVAN in the setting of sub-acute HIV 
infection. Additional high quality studies and randomized 
clinical trials are needed to establish treatment beyond 
HAART for HIVAN, taking into account the recent 
progress in the understanding of the pathogenesis of 
HIVAN in the existing body of literature. Furthermore, it 
is still not clear which of the combination antiretroviral 
therapies (cART) available are effective in treating HIVAN 
and to what extent they are achieving survival and 
morbidity reductions.
SuMMary
This case serves as an example of an uncommon 
yet dangerous complication of HIV. In the setting of 
nephrotic syndrome, screening for HIV infection and 
ruling out HIVAN in HIV-infected individuals is essential. 
HIVAN may be the first manifestation of HIV-1 infection 
in an otherwise asymptomatic patient and preservation 
of renal function in African Americans with chronic 
kidney disease and HIV is dependent upon its prompt 
recognition and early treatment. Early recognition 
and treatment of HIVAN has the potential to delay the 
onset of ESRD and improve mortality associated with 
complications of HIV.
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Figure 1. Trend of serum 
creatinine (Cr) (normal 
range: 0.7-1.3 mg/dL) 
and serum urea-nitrogen 
(mg/dL) (normal range: 
8 - 2 0  m g / d L )  s i n c e 
presentation to the ED 
(day 0) across time (days).
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